Springer Protocols: Abstract: 10. From Pharmacogenomics to Translational Biomarkers

10. From Pharmacogenomics to Translational Biomarkers

By: Donna L. Mendrick⁴

Abstract

Full Text

Download PDF (2016K)

There is a need for new biomarkers to enable faster detection of adverse events due to drugs and disease processes. One would prefer biomarkers that are useful in multiple species (i.e., translational or bridging biomarkers) so that it would be possible to directly link responses between species and follow such injury in both preclinical and clinical settings. This chapter will explore some of the issues surrounding the use of pharmacogenomics to identify and qualify such biomarkers, and examples will be provided.

Affiliation(s): (4) Department of Toxicogenomics, Gene Logic Inc., Gaithersburg, Maryland

Book Title: Essential Concepts in Toxicogenomics

Series: Methods in Molecular Biology | Volume: 460 | Pub. Date: Oct-01-2008 | Page Range: 195-220 | DOI: 10.1007/978-1-60327-048-9_10

Subject: Pharmacology/Toxicology

Key Words: biomarkers - pharmacogenomics - toxicogenomics - translational

References

Download References

1.	Vaidya, V.S. and Bonventre, J.V. (2006) Mechanistic biomarkers forcytotoxic acute kidney injury. Expert. Opin. Drug Metab.Toxicol. 2, 697–713.

2.	Ichimura, T., Bonventre, J.V., Bailly, V., Wei, H., Hession, C.A., Cate, R.L., and Sanicola, M. (1998) Kidney injury molecule-1(KIM-1), a putative epithelial cell adhesion molecule containing anovel immunoglobulin domain, is up-regulated in renal cells afterinjury. J. Biol. Chem. 273, 4135–4142.

3.	Amin, R.P., Vickers, A.E., Sistare, F., Thompson, K.L., Roman, R.J.,Lawton, M., et al. (2004) Identification of putative gene basedmarkers of renal toxicity. Environ. Health Perspect. 112, 465–479.

4.	Bailly, V., Zhang, Z., Meier, W., Cate, R., Sanicola, M., andBonventre, J.V. (2002) Shedding of kidney injury molecule-1, aputative adhesion protein involved in renal regeneration. J.Biol. Chem. 277, 39739–39748.

5.	Davis, J.W., Goodsaid, F.M., Bral, C.M., Obert, L.A., Mandakas, G.,Garner, C.E., et al. (2004) Quantitative gene expression analysis ina nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 200, 16–26.

6.	Han, W.K., Bailly, V., Abichandani, R., Thadhani, R., and Bonventre,J.V. (2002) Kidney injury molecule-1 (KIM-1): a novel biomarker forhuman renal proximal tubule injury. Kidney Int. 62,237–244.

7.	Ichimura, T., Hung, C.C., Yang, S.A., Stevens, J.L., and Bonventre,J.V. (2004) Kidney injury molecule-1: a tissue and urinary biomarkerfor nephrotoxicant-induced renal injury. Am. J. Physiol. RenalPhysiol. 286, F552–F563.

8.	Kuehn, E.W., Park, K.M., Somlo, S., and Bonventre, J.V. (2002)Kidney injury molecule-1 expression in murine polycystic kidneydisease. Am. J. Physiol. Renal Physiol. 283, F1326–F1336.

9.	Liangos, O., Perianayagam, M.C., Vaidya, V.S., Han, W.K., Wald, R.,Tighiouart, H., et al. (2007) UrinaryN-acetyl-beta-(D)-Glucosaminidase activity and kidney injurymolecule-1 level are associated with adverse outcomes in acute renalfailure. J. Am. Soc. Nephrol. 18, 904–912.

10.	Vaidya, V.S., Ramirez, V., Ichimura, T., Bobadilla, N.A., andBonventre, J.V. (2006) Urinary kidney injury molecule-1: a sensitivequantitative biomarker for early detection of kidney tubular injury.Am. J. Physiol. Renal Physiol. 290, F517–F529.}

11.	Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja,G., et al. (2000) Concordance of the toxicity of pharmaceuticals inhumans and in animals. Regul. Toxicol. Pharmacol. 32,56–67.

12.	Evans, R.W., Williams, G.E., Baron, H.M., Deng, M.C., Eisen, H.J.,Hunt, S.A., et al. (2005) The economic implications of noninvasivemolecular testing for cardiac allograft rejection. Am. J.Transplant. 5, 1553–1558.

13.	Starling, R.C., Pham, M., Valantine, H., Miller, L., Eisen, H.,Rodriguez, E.R., et al. (2006) Molecular testing in the managementof cardiac transplant recipients: initial clinical experience. J. Heart Lung Transplant. 25, 1389–1395.

14.	Baron, C., Somogyi, R., Greller, L.D., Rineau, V., Wilkinson, P.,Cho, C.R., et al. (2007) Prediction of graft-versus-host disease inhumans by donor gene-expression profiling. PLoS Med. 4,e23.

15.	Baird, A.E. (2007) Blood genomics in human stroke. Stroke 38, 694–698.

16.	Burczynski, M.E. and Dorner, A.J. (2006) Transcriptional profilingof peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 7, 187–202.

17.	McHale, C.M., Zhang, L., Hubbard, A.E., Zhao, X., Baccarelli, A.,Pesatori, A.C., et al. (2007) Microarray analysis of gene expressionin peripheral blood mononuclear cells from dioxin-exposed humansubjects. Toxicology 229, 101–113.

18.	Bushel, P.R., Heinloth, A.N., Li, J., Huang, L., Chou, J.W.,Boorman, G.A. et al. (2007) Blood gene expression signatures predictexposure levels. Proc. Natl. Acad. Sci U.S.A 104,18211–18216.

19.	Searfoss, G.H., Jordan, W.H., Calligaro, D.O., Galbreath, E.J.,Schirtzinger, L.M., Berridge, B.R., et al. (2003) Adipsin, abiomarker of gastrointestinal toxicity mediated by a functionalgamma-secretase inhibitor. J. Biol. Chem. 278,46107–46116.

20.	Milano, J., McKay, J., Dagenais, C., Foster-Brown, L., Pognan, F.,Gadient, R., et al. (2004) Modulation of notch processing bygamma-secretase inhibitors causes intestinal goblet cell metaplasiaand induction of genes known to specify gut secretory lineagedifferentiation. Toxicol. Sci. 82, 341–358.

21.	Lin, F., Zhang, P.L., Yang, X.J., Shi, J., Blasick, T., Han, W.K., et al. (2007) Human kidney injury molecule-1 (hKIM-1): a usefulimmunohistochemical marker for diagnosing renal cell carcinoma andovarian clear cell carcinoma. Am. J. Surg. Pathol. 31,371–381.

22.	Mendrick, D.L. and Daniels, K.K. (2007) From the bench to the clinicand back again: translational biomarker discovery using insilicomining of pharmacogenomic data. Biomarkers Med. 1, 319–333.

23.	Gielen, A.W., Lobell, A., Lidman, O., Khademi, M., Olsson, T., andPiehl, F. (2005) Expression of T cell immunoglobulin- andmucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the ratnervous and immune systems. J. Neuroimmunol. 164,93–104.

24.	de Souza, A.J., Oriss, T.B., O’malley, K.J., Ray, A., and Kane, L.P.(2005) T cell Ig and mucin 1 (TIM-1) is expressed on invivo-activated T cells and provides a costimulatory signal for Tcell activation. Proc. Natl. Acad. Sci U. S. A. 102,17113–17118.

25.	Meyers, J.H., Sabatos, C.A., Chakravarti, S., and Kuchroo, V.K.(2005) The TIM gene family regulates autoimmune and allergicdiseases. Trends Mol. Med. 11, 362–369.

26.	Thompson, K.L., Afshari, C.A., Amin, R.P., Bertram, T.A., Car, B.,Cunningham, M., et al. (2004) Identification of platform-independentgene expression markers of cisplatin nephrotoxicity. Environ.Health Perspect. 112, 488–494.

27.	Emanuelli, G., Anfossi, G., Calcamuggi, G., Marcarino, C., Ottone,G., and Dughera, L. (1985) Urinary enzyme excretion in acute andsubacute experimental lithium administration. Enzyme 34,177–185.

28.	Cornin, R.E. and Henrich, W.L.(1996) Toxic nephropathy. In: TheKidney(Brenner, B.M., ed.), W.B. Saunders, Philadelphia,pp. 1680–1711.

29.	Goldstein, R.S. and Schnellmann, R.G.(1996) Toxic responses of thekidney. In: Toxicology. The Basic Science of Poisons(Klaassen, C.D., ed.), McGraw-Hill, New York, pp. 417–442.

30.	Friedl, A., Stoesz, S.P., Buckley, P., and Gould, M.N. (1999)Neutrophil gelatinase-associated lipocalin in normal and neoplastichuman tissues. Cell type-specific pattern of expression. Histochem. J. 31, 433–441.

31.	Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J.,et al. (2003) Identification of neutrophil gelatinase-associatedlipocalin as a novel early urinary biomarker for ischemic renalinjury. J. Am. Soc. Nephrol. 14, 2534–2543.

32.	Schmidt-Ott, K.M., Mori, K., Li, J.Y., Kalandadze, A., Cohen, D.J.,Devarajan, P., and Barasch, J. (2007) Dual action of neutrophilgelatinase-associated lipocalin. J. Am. Soc. Nephrol. 18, 407–413.

33.	Lau, L.F. and Lam, S.C. (1999) The CCN family of angiogenicregulators: the integrin connection. Exp. Cell Res. 248,44–57.

34.	Menendez, J.A., Mehmi, I., Griggs, D.W., and Lupu, R. (2003) Theangiogenic factor CYR61 in breast cancer: molecular pathology andtherapeutic perspectives. Endocr. Relat. Cancer 10,141–152.

35.	Muramatsu, Y., Tsujie, M., Kohda, Y., Pham, B., Perantoni, A.O.,Zhao, H., et al. (2002) Early detection of cysteine rich protein 61(CYR61, CCN1) in urine following renal ischemic reperfusion injury.Kidney Int. 62, 1601–1610.

36.	Salerno, R.A. and Lesko, L.J. (2004) Pharmacogenomics in drugdevelopment and regulatory decision-making: the Genomic DataSubmission (GDS) Proposal. Pharmacogenomics 5, 25–30.

37.	Leighton, J.K., DeGeorge, J., Jacobson-Kram, D., MacGregor, J.,Mendrick, D., and Worobec, A. (2004) Pharmacogenomic datasubmissions to the FDA: non-clinical case studies. Pharmacogenomics 5, 507–511.

38.	Trepicchio, W.L., Williams, G.A., Essayan, D., Hall, S.T., Harty,L.C., Shaw, P.M., et al. (2004) Pharmacogenomic data submissions tothe FDA: clinical case studies. Pharmacogenomics 5,519–524.

39.	Ruano, G., Collins, J.M., Dorner, A.J., Wang, S.J., Guerciolini, R.,and Huang, S.M. (2004) Pharmacogenomic data submissions to the FDA:clinical pharmacology case studies. Pharmacogenomics 5,513–517.

40.	Mendrick, D.L., Brazell, C., Mansfield, E.A., Pietrusko, R.,Barilero, I., Hackett, J., et al. (2006) Pharmacogenomics andregulatory decision making: an international perspective. Pharmacogenomics J. 6, 154–157.

41.	Salerno, R.A. and Lesko, L.J. (2006) Three years of promise,proposals, and progress on optimizing the benefit/risk of medicines:a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomicsworkshop. Pharmacogenomics J. 6, 78–81.

42.	Frueh, F.W., Rudman, A., Simon, K., Gutman, S., Reed, C., andDorner, A.J. (2006) Experience with voluntary and required genomicdata submissions to the FDA: summary report from track 1 of thethird FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J. 6, 296–300.

43.	Simon, R. and Wang, S.J. (2006) Use of genomic signatures intherapeutics development in oncology and other diseases. Pharmacogenomics J. 6, 166–173.

44.	Hinman, L.M., Huang, S.M., Hackett, J., Koch, W.H., Love, P.Y.,Pennello, G., et al. (2006) The drug diagnostic co-developmentconcept paper Commentary from the 3rd FDA-DIA-PWG-PhRMA-BIOPharmacogenomics Workshop. Pharmacogenomics J. 6,375–380.

45.	Trepicchio, W.L., Essayan, D., Hall, S.T., Schechter, G., Tezak, Z.,Wang, S.J., et al. (2006) Designing prospective clinicalpharmacogenomic (PG) trials: meeting report on drug developmentstrategies to enhance therapeutic decision making. Pharmacogenomics J. 6, 89–94.

46.	Goodsaid, F. and Frueh, F. (2006) Process map proposal for thevalidation of genomic biomarkers. Pharmacogenomics 7,773–782.

Comments (Loading...)

Post comment/View all comments